Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 2:44 PM ET


Company Overview of Audentes Therapeutics, Inc.

Company Overview

Audentes Therapeutics, Inc. a biotechnology company, is engaged in the development and commercialization of new gene therapy treatments for people with serious rare diseases. It is engaged in the development of AT001 for the treatment of X-linked myotubular myopathy; AT002 for the treatment of pompe disease; and AT003 for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. was founded in 2012 and is based in San Francisco, California.

101 Montgomery Street

Suite 2650

San Francisco, CA 94104

United States

Founded in 2012





Key Executives for Audentes Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 43
Chief Financial Officer
Age: 48
Chief Operating Officer
Age: 42
Chief Medical Officer and Senior Vice President
Senior Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2015.

Audentes Therapeutics, Inc. Key Developments

Audentes Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:15 PM

Audentes Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:15 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Genine Winslow, Director of Research Analytics.

Audentes Therapeutics, Inc. Announces Management Appointments

Audentes Therapeutics, Inc. announced the addition of three accomplished biopharmaceutical executives to its leadership team. Natalie Holles has joined Audentes as Senior Vice President and Chief Operating Officer, Thomas Soloway has joined as Senior Vice President and Chief Financial Officer and Kevin Baker, Ph.D. has joined as Senior Vice President, Preclinical Development. In these newly created roles, each will report to Matthew Patterson, President and Chief Executive Officer of Audentes Therapeutics, Inc. Ms. Holles joins Audentes with over 15 years of corporate development, strategic planning, and commercial experience, gained in a range of therapeutic areas and with a focus on orphan diseases. Most recently, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010-2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies, most recently acting as Executive Vice President, Corporate Development at Immune Design, Inc. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. Mr. Soloway joins Audentes with over 20 years of experience in operations, corporate finance, and venture capital related to the life sciences industry. Prior to joining Audentes, Mr. Soloway served as the Senior Vice President, Chief Financial Officer of Ascendis Pharma A/S, a Danish biopharmaceutical company, where he helped lead a successful initial public offering on NASDAQ. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc. Dr. Baker joins Audentes with over 20 years of experience in the discovery and development of novel biologic drugs for a wide range of diseases. Dr. Baker most recently served as Vice President, Preclinical Development at FivePrime Therapeutics, Inc.

Audentes Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 08:50 AM

Audentes Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 08:50 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Matthew R. Patterson, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
ViaGen, Inc. United States
Pasteuria Bioscience, Inc. United States
Galera Therapeutics, Inc. United States
Glycosan BioSystems, Inc. United States
Primogenix Inc. United States

Recent Private Companies Transactions

Private Placement
October 8, 2015
August 31, 2015
Cardiogen Sciences, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Audentes Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at